Indiziert in
- Öffnen Sie das J-Tor
- Genamics JournalSeek
- Akademische Schlüssel
- JournalTOCs
- Forschungsbibel
- Elektronische Zeitschriftenbibliothek
- RefSeek
- Hamdard-Universität
- EBSCO AZ
- OCLC – WorldCat
- Proquest-Vorladungen
- SWB Online-Katalog
- Virtuelle Bibliothek für Biologie (vifabio)
- Publons
- MIAR
- Euro-Pub
- Google Scholar
Nützliche Links
Teile diese Seite
Zeitschriftenflyer
Open-Access-Zeitschriften
- Allgemeine Wissenschaft
- Biochemie
- Bioinformatik und Systembiologie
- Chemie
- Genetik und Molekularbiologie
- Immunologie und Mikrobiologie
- Klinische Wissenschaften
- Krankenpflege und Gesundheitsfürsorge
- Landwirtschaft und Aquakultur
- Lebensmittel & Ernährung
- Maschinenbau
- Materialwissenschaften
- Medizinische Wissenschaften
- Neurowissenschaften und Psychologie
- Pharmazeutische Wissenschaften
- Umweltwissenschaften
- Veterinärwissenschaften
- Wirtschaft & Management
Abstrakt
Pharmacogenomic Analysis Identifies Increased Efficacy of Oxaliplatin in ABCB1 Overexpressing Tumors
Anh-Nhan Pham, Mingju Cao, Paul E. Blower, Moses S. Chow and Ying Huang
Oxaliplatin is a platinum-class drug used for advanced colorectal cancer, which is still incurable because ofdrug resistance. We applied a pharmacogenomic approach to correlate mRNA expression profiles of transportergenes and growth inhibitory potency of oxaliplatin in NCI-60. Expression of ABCB1 (MDR1, P-glycoprotein) genepositively correlated with anticancer activity of oxaliplatin, but not with cisplatin and other platinum analogs. Thiscorrelation suggests that cell lines with higher ABCB1 expression were more sensitive to oxaliplatin. MDR1 inhibitorscyclosporine A, PSC 833 or verapamil significantly reduced the sensitivity to oxaliplatin in ABCB1 overexpressingovarian cancer cell line NCI/ADR-RES and colon cancer cell line HCT-15, whereas increased the sensitivity to MDR1 substrate drugs. These results provide evidence that the effect of oxaliplatin may be selective for tumor cells with high level of ABCB1 and overcome drug resistance. Such finding may provide an exciting prospect for future individualization of oxaliplatin-based cancer therapy.